BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32075387)

  • 1. The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology.
    Boudny M; Trbusek M
    Klin Onkol; 2020; 33(1):32-38. PubMed ID: 32075387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.
    Frank DA; Mahajan S; Ritz J
    J Clin Invest; 1997 Dec; 100(12):3140-8. PubMed ID: 9399961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.
    Hazan-Halevy I; Harris D; Liu Z; Liu J; Li P; Chen X; Shanker S; Ferrajoli A; Keating MJ; Estrov Z
    Blood; 2010 Apr; 115(14):2852-63. PubMed ID: 20154216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
    Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
    Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
    Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
    Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
    Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
    Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Targeted treatment of chronic lymphocytic leukaemia].
    Niemann CU
    Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.
    Rozovski U; Harris DM; Li P; Liu Z; Jain P; Veletic I; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
    Int J Cancer; 2017 Nov; 141(10):2076-2081. PubMed ID: 28722170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.
    Lee YK; Shanafelt TD; Bone ND; Strege AK; Jelinek DF; Kay NE
    Leukemia; 2005 Apr; 19(4):513-23. PubMed ID: 15703780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo.
    Lin F; Wu D; Fang D; Chen Y; Zhou H; Ou C
    Inflamm Res; 2019 Sep; 68(9):739-749. PubMed ID: 31218443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.
    Wu Z; Wang L; Fan L; Tang H; Zuo X; Gu D; Lu X; Li Y; Wu J; Qin S; Xia Y; Zhu H; Wang L; Xu W; Li J; Jin H
    Mol Oncol; 2022 Aug; 16(16):2920-2935. PubMed ID: 35811334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment.
    Severin F; Frezzato F; Visentin A; Martini V; Trimarco V; Carraro S; Tibaldi E; Brunati AM; Piazza F; Semenzato G; Facco M; Trentin L
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viability and stress protection of chronic lymphoid leukemia cells involves overactivation of mitochondrial phosphoSTAT3Ser727.
    Capron C; Jondeau K; Casetti L; Jalbert V; Costa C; Verhoeyen E; Massé JM; Coppo P; Béné MC; Bourdoncle P; Cramer-Bordé E; Dusanter-Fourt I
    Cell Death Dis; 2014 Oct; 5(10):e1451. PubMed ID: 25299776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
    Rozovski U; Wu JY; Harris DM; Liu Z; Li P; Hazan-Halevy I; Ferrajoli A; Burger JA; O'Brien S; Jain N; Verstovsek S; Wierda WG; Keating MJ; Estrov Z
    Blood; 2014 Jun; 123(24):3797-802. PubMed ID: 24778152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    Martini V; Gattazzo C; Frezzato F; Trimarco V; Pizzi M; Chiodin G; Severin F; Scomazzon E; Guzzardo V; Saraggi D; Raggi F; Martinello L; Facco M; Visentin A; Piazza F; Brunati AM; Semenzato G; Trentin L
    Br J Haematol; 2017 Jul; 178(1):81-93. PubMed ID: 28419476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.